Work

AML-534: Superior Preclinical Efficacy of BRG1/BRM Inhibitor Combined With BET Inhibitor or Decitabine Against MECOM-rearranged (MECOMr) Acute Myeloid Leukemia (AML)

Year: 2025

Type: conference-abstract

Source: Clinical Lymphoma Myeloma & Leukemia

DOI: 10.1016/s2152-2650(25)01686-6

Authors: Warren Fiskus, Christopher Mill, Jessica Piel, Murphy Hentemann, Christine Birdwell, Kaberi Das, Hanxi Hou, John Davis, Tapan Kadia, Naval Daver, Sanam Loghavi, Courtney DiNardo, Kapil Bhalla

Institutions: The University of Texas MD Anderson Cancer Center, Foghorn Therapeutics (United States)

Language: English

Topic: Acute Myeloid Leukemia Research

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4413792278

Cites:

Cited by:

Related to: 10